Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Spirometry | Research

Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment

Authors: Asako Yanagisawa, Akira Naito, Takayuki Jujo-Sanada, Nobuhiro Tanabe, Keiichi Ishida, Goro Matsumiya, Rika Suda, Hajime Kasai, Ayumi Sekine, Toshihiko Sugiura, Ayako Shigeta, Seiichiro Sakao, Koichiro Tatsumi, Takuji Suzuki

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Chronic thromboembolic pulmonary hypertension (CTEPH) is a type of pulmonary hypertension caused by persistent thromboembolism of the pulmonary arteries. In clinical practice, CTEPH patients often show obstructive ventilatory impairment, even in the absence of a smoking history. Recent reports imply a tendency for CTEPH patients to have a lower FEV1.0; however, the mechanism underlying obstructive impairment remains unknown.

Methods

We retrospectively analyzed CTEPH patients who underwent a pulmonary function test and respiratory impedance test to evaluate their exertional dyspnea during admission for right heart catheterization from January 2000 to December 2019. We excluded patients with a smoking history to rule out the effect of smoking on obstructive impairment.

Results

A total of 135 CTEPH patients were analyzed. The median FEV1.0/FVC was 76.0%, %FEV 1.0 had a negative correlation with the mean pulmonary artery pressure and pulmonary vascular resistance and the CT Angiogram (CTA) obstruction score. A multivariate regression analysis revealed that the CTA obstruction score was an independent factor of a lower %FEV1.0. In the 54 patients who underwent pulmonary endarterectomy, %FEV1.0 was improved in some cases and was not in some. Mean PAP largely decreased after PEA in the better %FEV1.0 improved cases, suggesting that vascular involvement in CTEPH could be associated with spirometry obstructive impairment.

Conclusion

%FEV1.0 had a significant correlation with the CTA obstruction score. Obstructive impairment might have an etiological relationship with vascular involvement. Further investigations could shed new light on the etiology of CTEPH.
Appendix
Available only for authorised users
Literature
1.
go back to reference Witkin AS, Channick RN. Chronic thromboembolic pulmonary hypertension: the end result of pulmonary embolism. Curr Cardiol Rep. 2015;17:63.CrossRef Witkin AS, Channick RN. Chronic thromboembolic pulmonary hypertension: the end result of pulmonary embolism. Curr Cardiol Rep. 2015;17:63.CrossRef
2.
go back to reference Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462–8.CrossRef Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462–8.CrossRef
3.
go back to reference Haoming S, Lemin W, Zhu G, Aibin L, Yuan X, Wei L, et al. T cell-mediated immune deficiency or compromise in patients with CTEPH. Am J Respir Crit Care Med. 2011;183:417–8.CrossRef Haoming S, Lemin W, Zhu G, Aibin L, Yuan X, Wei L, et al. T cell-mediated immune deficiency or compromise in patients with CTEPH. Am J Respir Crit Care Med. 2011;183:417–8.CrossRef
4.
go back to reference Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325–31.CrossRef Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325–31.CrossRef
5.
go back to reference Fernandes T, Auger W, Fedullo P. Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. Thromb Res. 2018;164:145–9.CrossRef Fernandes T, Auger W, Fedullo P. Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. Thromb Res. 2018;164:145–9.CrossRef
6.
go back to reference Palkar AV, Agrawal A, Verma S, Iftikhar A, Miller EJ, Talwar A. Post splenectomy related pulmonary hypertension. World J Respirol. 2015;5:69–77.CrossRef Palkar AV, Agrawal A, Verma S, Iftikhar A, Miller EJ, Talwar A. Post splenectomy related pulmonary hypertension. World J Respirol. 2015;5:69–77.CrossRef
7.
go back to reference Yan L, Li X, Liu Z, Zhao Z, Luo Q, Zhao Q, et al. Research progress on the pathogenesis of CTEPH. Heart Fail Rev. 2019;24:1031–40.CrossRef Yan L, Li X, Liu Z, Zhao Z, Luo Q, Zhao Q, et al. Research progress on the pathogenesis of CTEPH. Heart Fail Rev. 2019;24:1031–40.CrossRef
8.
go back to reference Sato S, Sugiura T, Tanabe N, Terada J, Sakao S, Kasahara Y, et al. Successful operative case of chronic thromboembolic pulmonary hypertension clinically diagnosed as bronchial asthma. Nihon Kokyuki Gakkai Zasshi. 2010;48:836–41.PubMed Sato S, Sugiura T, Tanabe N, Terada J, Sakao S, Kasahara Y, et al. Successful operative case of chronic thromboembolic pulmonary hypertension clinically diagnosed as bronchial asthma. Nihon Kokyuki Gakkai Zasshi. 2010;48:836–41.PubMed
9.
go back to reference Fukushi K, Kataoka M, Shimura N, Inami T, Fukuda K, Yoshino H, et al. Impaired respiratory function in chronic thromboembolic pulmonary hypertension: a comparative study with healthy control subjects. Ann Am Thorac Soc. 2016;13:1183–4.CrossRef Fukushi K, Kataoka M, Shimura N, Inami T, Fukuda K, Yoshino H, et al. Impaired respiratory function in chronic thromboembolic pulmonary hypertension: a comparative study with healthy control subjects. Ann Am Thorac Soc. 2016;13:1183–4.CrossRef
10.
go back to reference Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRef Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRef
11.
go back to reference Jujo T, Sakao S, Ishibashi-Ueda H, Ishida K, Naito A, Sugiura T, et al. Evaluation of the microcirculation in chronic thromboembolic pulmonary hypertension patients: the impact of pulmonary arterial remodeling on postoperative and follow-up pulmonary arterial pressure and vascular resistance. PLoS ONE. 2015;10:e0133167.CrossRef Jujo T, Sakao S, Ishibashi-Ueda H, Ishida K, Naito A, Sugiura T, et al. Evaluation of the microcirculation in chronic thromboembolic pulmonary hypertension patients: the impact of pulmonary arterial remodeling on postoperative and follow-up pulmonary arterial pressure and vascular resistance. PLoS ONE. 2015;10:e0133167.CrossRef
12.
go back to reference Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, et al. New CT index to quantify arterial obstruction in pulmonary embolism. Am J Roentgenol. 2001;176:1415–20.CrossRef Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, et al. New CT index to quantify arterial obstruction in pulmonary embolism. Am J Roentgenol. 2001;176:1415–20.CrossRef
13.
go back to reference Jujo T, Tanabe N, Sakao S, Ishibashi-Ueda H, Ishida K, Naito A, et al. Severe pulmonary arteriopathy is associated with persistent hypoxemia after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. PLoS ONE. 2016;11:e0161827–e0161827.CrossRef Jujo T, Tanabe N, Sakao S, Ishibashi-Ueda H, Ishida K, Naito A, et al. Severe pulmonary arteriopathy is associated with persistent hypoxemia after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. PLoS ONE. 2016;11:e0161827–e0161827.CrossRef
14.
go back to reference Anazawa R, Kawata N, Matsuura Y, Ikari J, Tada Y, Suzuki M, et al. Longitudinal changes in structural lung abnormalities using MDCT in chronic obstructive pulmonary disease with asthma-like features. PLoS ONE. 2019;14:e0227141.CrossRef Anazawa R, Kawata N, Matsuura Y, Ikari J, Tada Y, Suzuki M, et al. Longitudinal changes in structural lung abnormalities using MDCT in chronic obstructive pulmonary disease with asthma-like features. PLoS ONE. 2019;14:e0227141.CrossRef
15.
go back to reference Sakurai-Iesato Y, Kawata N, Tada Y, Iesato K, Matsuura Y, Yahaba M, et al. The relationship of bone mineral density in men with chronic obstructive pulmonary disease classified according to the global initiative for chronic obstructive lung disease (GOLD) combined chronic obstructive pulmonary disease (COPD) assessment system. Intern Med. 2017;56:1781–90.CrossRef Sakurai-Iesato Y, Kawata N, Tada Y, Iesato K, Matsuura Y, Yahaba M, et al. The relationship of bone mineral density in men with chronic obstructive pulmonary disease classified according to the global initiative for chronic obstructive lung disease (GOLD) combined chronic obstructive pulmonary disease (COPD) assessment system. Intern Med. 2017;56:1781–90.CrossRef
16.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef
17.
go back to reference Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig. 2014;52:242–50.CrossRef Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig. 2014;52:242–50.CrossRef
18.
go back to reference [Guideline of respiratory function tests--spirometry, flow-volume curve, diffusion capacity of the lung]. Nihon Kokyuki Gakkai Zasshi 2004, Suppl:1–56. [Guideline of respiratory function tests--spirometry, flow-volume curve, diffusion capacity of the lung]. Nihon Kokyuki Gakkai Zasshi 2004, Suppl:1–56.
19.
go back to reference Oostveen E, MacLeod D, Lorino H, Farré R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22:1026–41.CrossRef Oostveen E, MacLeod D, Lorino H, Farré R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22:1026–41.CrossRef
20.
go back to reference Takei M, Kawakami T, Kataoka M, Kuwahira I, Fukuda K. Residual high intrapulmonary shunt fraction limits exercise capacity in patients treated with balloon pulmonary angioplasty. Heart Vessels. 2019;34:868–74.CrossRef Takei M, Kawakami T, Kataoka M, Kuwahira I, Fukuda K. Residual high intrapulmonary shunt fraction limits exercise capacity in patients treated with balloon pulmonary angioplasty. Heart Vessels. 2019;34:868–74.CrossRef
21.
go back to reference Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–92.CrossRef Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–92.CrossRef
22.
go back to reference Lang IM, Dorfmüller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13(Suppl 3):S215-221.CrossRef Lang IM, Dorfmüller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13(Suppl 3):S215-221.CrossRef
23.
go back to reference Bergin CJ, Rios G, King MA, Belezzuoli E, Luna J, Auger WR. Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR Am J Roentgenol. 1996;166:1371–7.CrossRef Bergin CJ, Rios G, King MA, Belezzuoli E, Luna J, Auger WR. Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR Am J Roentgenol. 1996;166:1371–7.CrossRef
24.
go back to reference Grosse C, Grosse A. CT findings in diseases associated with pulmonary hypertension: a current review. Radiographics. 2010;30:1753–77.CrossRef Grosse C, Grosse A. CT findings in diseases associated with pulmonary hypertension: a current review. Radiographics. 2010;30:1753–77.CrossRef
25.
go back to reference Grosse A, Grosse C, Lang IM. Distinguishing chronic thromboembolic pulmonary hypertension from other causes of pulmonary hypertension using CT. AJR Am J Roentgenol. 2017;209:1228–38.CrossRef Grosse A, Grosse C, Lang IM. Distinguishing chronic thromboembolic pulmonary hypertension from other causes of pulmonary hypertension using CT. AJR Am J Roentgenol. 2017;209:1228–38.CrossRef
26.
go back to reference Grosse A, Grosse C, Lang I. Evaluation of the CT imaging findings in patients newly diagnosed with chronic thromboembolic pulmonary hypertension. PLoS ONE. 2018;13:e0201468–e0201468.CrossRef Grosse A, Grosse C, Lang I. Evaluation of the CT imaging findings in patients newly diagnosed with chronic thromboembolic pulmonary hypertension. PLoS ONE. 2018;13:e0201468–e0201468.CrossRef
27.
go back to reference Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211–8.CrossRef Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211–8.CrossRef
28.
go back to reference Langer F, Schramm R, Bauer M, Tscholl D, Kunihara T, Schäfers HJ. Cytokine response to pulmonary thromboendarterectomy. Chest. 2004;126:135–41.CrossRef Langer F, Schramm R, Bauer M, Tscholl D, Kunihara T, Schäfers HJ. Cytokine response to pulmonary thromboendarterectomy. Chest. 2004;126:135–41.CrossRef
29.
go back to reference Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:319–24.CrossRef Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:319–24.CrossRef
30.
go back to reference Chen H, Tliba O, Van Besien CR, Panettieri RA Jr, Amrani Y. TNF-[alpha] modulates murine tracheal rings responsiveness to G-protein-coupled receptor agonists and KCl. J Appl Physiol (1985). 2003;95:864–72 (discussion 863).CrossRef Chen H, Tliba O, Van Besien CR, Panettieri RA Jr, Amrani Y. TNF-[alpha] modulates murine tracheal rings responsiveness to G-protein-coupled receptor agonists and KCl. J Appl Physiol (1985). 2003;95:864–72 (discussion 863).CrossRef
31.
go back to reference Goto K, Chiba Y, Matsusue K, Hattori Y, Maitani Y, Sakai H, et al. The proximal STAT6 and NF-kappaB sites are responsible for IL-13- and TNF-alpha-induced RhoA transcriptions in human bronchial smooth muscle cells. Pharmacol Res. 2010;61:466–72.CrossRef Goto K, Chiba Y, Matsusue K, Hattori Y, Maitani Y, Sakai H, et al. The proximal STAT6 and NF-kappaB sites are responsible for IL-13- and TNF-alpha-induced RhoA transcriptions in human bronchial smooth muscle cells. Pharmacol Res. 2010;61:466–72.CrossRef
32.
go back to reference Kudo M, Khalifeh Soltani SM, Sakuma SA, McKleroy W, Lee TH, Woodruff PG, et al. Mfge8 suppresses airway hyperresponsiveness in asthma by regulating smooth muscle contraction. Proc Natl Acad Sci USA. 2013;110:660–5.CrossRef Kudo M, Khalifeh Soltani SM, Sakuma SA, McKleroy W, Lee TH, Woodruff PG, et al. Mfge8 suppresses airway hyperresponsiveness in asthma by regulating smooth muscle contraction. Proc Natl Acad Sci USA. 2013;110:660–5.CrossRef
33.
go back to reference Frantz S, Nihlén U, Dencker M, Engström G, Löfdahl CG, Wollmer P. Impulse oscillometry may be of value in detecting early manifestations of COPD. Respir Med. 2012;106:1116–23.CrossRef Frantz S, Nihlén U, Dencker M, Engström G, Löfdahl CG, Wollmer P. Impulse oscillometry may be of value in detecting early manifestations of COPD. Respir Med. 2012;106:1116–23.CrossRef
34.
go back to reference Nilsson AM, Theander E, Hesselstrand R, Piitulainen E, Wollmer P, Mandl T. The forced oscillation technique is a sensitive method for detecting obstructive airway disease in patients with primary Sjogren’s syndrome. Scand J Rheumatol. 2014;43:324–8.CrossRef Nilsson AM, Theander E, Hesselstrand R, Piitulainen E, Wollmer P, Mandl T. The forced oscillation technique is a sensitive method for detecting obstructive airway disease in patients with primary Sjogren’s syndrome. Scand J Rheumatol. 2014;43:324–8.CrossRef
35.
go back to reference Cottee AM, Seccombe LM, Thamrin C, King GG, Peters MJ, Farah CS. Bronchodilator response assessed by the forced oscillation technique identifies poor asthma control with greater sensitivity than spirometry. Chest. 2020;157:1435–41.CrossRef Cottee AM, Seccombe LM, Thamrin C, King GG, Peters MJ, Farah CS. Bronchodilator response assessed by the forced oscillation technique identifies poor asthma control with greater sensitivity than spirometry. Chest. 2020;157:1435–41.CrossRef
36.
go back to reference Shirai T, Mori K, Mikamo M, Shishido Y, Akita T, Morita S, et al. Respiratory mechanics and peripheral airway inflammation and dysfunction in asthma. Clin Exp Allergy. 2013;43:521–6.CrossRef Shirai T, Mori K, Mikamo M, Shishido Y, Akita T, Morita S, et al. Respiratory mechanics and peripheral airway inflammation and dysfunction in asthma. Clin Exp Allergy. 2013;43:521–6.CrossRef
37.
go back to reference Shirai T, Kurosawa H. Clinical application of the forced oscillation technique. Intern Med. 2016;55:559–66.CrossRef Shirai T, Kurosawa H. Clinical application of the forced oscillation technique. Intern Med. 2016;55:559–66.CrossRef
38.
go back to reference Mori K, Shirai T, Mikamo M, Shishido Y, Akita T, Morita S, et al. Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma. COPD. 2011;8:456–63.CrossRef Mori K, Shirai T, Mikamo M, Shishido Y, Akita T, Morita S, et al. Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma. COPD. 2011;8:456–63.CrossRef
Metadata
Title
Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment
Authors
Asako Yanagisawa
Akira Naito
Takayuki Jujo-Sanada
Nobuhiro Tanabe
Keiichi Ishida
Goro Matsumiya
Rika Suda
Hajime Kasai
Ayumi Sekine
Toshihiko Sugiura
Ayako Shigeta
Seiichiro Sakao
Koichiro Tatsumi
Takuji Suzuki
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01779-x

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.